We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

- Glioblastoma Multiforme | Anaplastic Astrocytoma|Anaplastic Oligodendroglioma | Anaplastic Mixed Oligoastrocytoma
- Terminated

Study Title: Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Teva Identifier: IXR-205-21-189

ClinicalTrials.gov Identifier: NCT00062504

Study Status: Terminated

Trial Condition(s): Glioblastoma Multiforme | Anaplastic Astrocytoma|Anaplastic Oligodendroglioma | Anaplastic Mixed Oligoastrocytoma

Interventions: Drug: Talampanel

Study Description: Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

cancer icon for clinical trials

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years and older

Trial Duration: 07/01/2003 - 04/01/2006

Phase: Phase 2

Study Type

Interventional